Posterior Reversible Leukoencephalopathy Syndrome in a Patient after Acute COVID-19 Infection

Table 1

Clinical characteristics during initial hospitalization and readmission.

Variables	Initial admission	Readmission
Reason for admission	Fever	Seizure
Comorbidities	HTN, osteoarthritis, DM 2, VTE, CKD stage 2, atrial flutter, cataract, macular degeneration, right eye blindness, pressure ulcer stage II, mild dementia	HTN, osteoarthritis, DM 2, VTE, CKD stage 2, atrial flutter, cataract, macular degeneration, right eye blindness, pressure ulcer stage II, mild dementia
COVID-19 PCR	Positive; At discharge: negative	Not tested
Symptoms of COVID-19	Fever and cough, acute, respiratory failure, altered mental status	NA
Hospital problem list	Acute respiratory failure, viral pneumonia, acute diffuse body pain, DM 2, HTN, acute renal failure, delirium, cystitis, hypokalemia	New-onset seizure, acute metabolic encephalopathy, cystitis, hypomagnesemia, hypokalemia
Risk factors for PRES	N/A	BP fluctuations, recent COVID-19 infection
The onset of PRES from diagnosing COVID-19	NA	31 days
LOS, total	22 days	6 days
LOS, ICU	2 days	0
LOS, floor	20 days	6 days
MAP, range	81–120	91–113
SBP, range	124–192	127–227
Medications	Acetaminophen, apixaban, ceftriaxone, insulin, labetalol, ondansetron, magnesium sulfate, potassium chloride, hydralazine, gabapentin, tramadol	Acetaminophen, apixaban, labetalol, ceftriaxone, insulin, levetiracetam, tramadol (stopped at admission)
Specific treatment for COVID-19	Enrolled in RESCUE trial: received single low-dose chest radiation